Barclays raised the firm’s price target on Regeneron to $1,200 from $1,050 and keeps an Overweight rating on the shares as part of a Q2 earnings preview for the U.S. biopharmaceutical space. The analyst believes Pfizer (PFE), Eli Lilly (LLY) and Merck (MRK) “are set up for compelling updates,” while Travere Therapeutics’ (TVTX) momentum should continue into the FDA action date.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- Regeneron, Sanofi announce EC approval for Dupixent
- Dupixent® (dupilumab) Approved in the European Union as the First-ever Targeted Therapy for Patients with COPD
- Odronextamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma
- Regeneron announces positive CHMP opinion for odronextamab
- Regeneron to Report Second Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2024